Kan, Karin
Wong, Danny Ka-Ho
Hui, Rex Wan-Hin
Seto, Wai Kay
Yuen, Man-Fung
Mak, Lung-Yi
Funding for this research was provided by:
General Research Fund, Research Grants Council, the gov of HKSAR
Seed Fund for Basic Research, The University of Hong Kong
Article History
Received: 6 July 2023
Accepted: 28 September 2023
First Online: 6 October 2023
Declarations
:
: Competing interests: D Wong has received compensation for speaking engagements from Abbott Laboratories. WK Seto has received speaker’s fees from AstraZeneca and Mylan, serves on the advisory board for CSL Behring, serves on the advisory board and has received speaker’s fees from AbbVie, and serves on the advisory board, has received speaker’s fees and research funding from Gilead Sciences. MF Yuen acts as an advisor/consultant for AbbVie, Assembly Biosciences, Aligos Therapeutics, Arbutus Biopharma, Bristol Myer Squibb, Clear B Therapeutics, Dicerna Pharmaceuticals, Finch Therapeutics, GlaxoSmithKline, Gilead Sciences, Immunocore, Janssen, Merck Sharp and Dohme, Hoffmann-La Roche and Springbank Pharmaceuticals, Vir Biotechnology and receives grant/research support from Assembly Biosciences, Aligos Therapeutics, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Immunocore, Merck Sharp and Dohme, Hoffmann-La Roche, Springbank Pharmaceuticals and Sysmex Corporation. The other authors do not have any conflicts of interest.
: The study follows the Declaration of Helsinki. This study received approval from The Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB). The IRB reference number is UW 20–426. All participants provided written informed consent.
: not applicable.